@ThePharmaLetter The Pharma Letter

The Pharma Letter posts on X about biotech, pharma, sanofi, ceo the most. They currently have [------] followers and [---] posts still getting attention that total [--] engagements in the last [--] hours.

Engagements: [--] #

[--] Week [-----] -16%
[--] Month [-----] +14%
[--] Months [------] +156%
[--] Year [------] +17%

Mentions: [--] #

[--] Week [--] +5.60%
[--] Month [---] +55%
[--] Months [---] +170%
[--] Year [---] +74%

Followers: [------] #

[--] Week [------] +0.01%
[--] Month [------] +0.14%
[--] Months [------] +0.88%
[--] Year [------] +2.30%

CreatorRank: [---------] #

Social Influence

Social category influence stocks 26.57% countries 12.56% finance 8.7% vc firms 0.97% financial services 0.48% exchanges 0.48% travel destinations 0.48%

Social topic influence biotech 11.59%, pharma 5.8%, sanofi #64, ceo 3.38%, japan 2.9%, novartis 2.9%, china 2.9%, gilead sciences 2.42%, in the 1.93%, center 1.45%

Top accounts mentioned or mentioned by @astrazeneca @novonordisk @gileadsciences @sanofi @pfizer @usfda @gsk @merckhealthcare @eisaius @amgen @merck @novartis @ifpma @biohavenpharma @soseiheptaresco @sironabiochem @sfabiotech @wuxibiologics @abbvie @regenxbio

Top assets mentioned Sanofi (SNY) Novartis AG (NVS) Gilead Sciences, Inc. (GILD) AbbVie Inc (ABBV) Bristol-Myers Squibb Co (BMY) Ocular Therapeutix, Inc. (OCUL)

Top Social Posts

Top posts by engagements in the last [--] hours

"@EisaiUS links up with cancer center to investigate cancer drug Tazverik https://www.thepharmaletter.com/article/eisai-links-up-with-cancer-center-to-investigate-cancer-drug-tazverik https://www.thepharmaletter.com/article/eisai-links-up-with-cancer-center-to-investigate-cancer-drug-tazverik"
X Link 2023-04-03T17:36Z 25.4K followers, [--] engagements

"Japanese deal gives @BiohavenPharma the edge in oral CGRP inhibition @soseiheptaresco https://www.thepharmaletter.com/article/japanese-deal-gives-biohaven-the-edge-in-oral-cgrp-inhibition https://www.thepharmaletter.com/article/japanese-deal-gives-biohaven-the-edge-in-oral-cgrp-inhibition"
X Link 2020-12-02T11:39Z 25.4K followers, [--] engagements

"UK backs Dupixent as first biologic for severe nasal polyps #Dupixent #Sanofi #Regeneron #Biologics #NasalPolyps #CRSwNP #ENT #Immunology #NHS #UKHealthcare #PharmaNews #DrugApproval #MarketAccess #Biotech #Healthcare https://www.thepharmaletter.com/biotech-news/uk-backs-dupilumab-as-first-biologic-for-severe-nasal-polyps https://www.thepharmaletter.com/biotech-news/uk-backs-dupilumab-as-first-biologic-for-severe-nasal-polyps"
X Link 2026-02-05T18:26Z 25.4K followers, [---] engagements

"Why global investors are turning to Egyptian pharma: a plant-level perspective from Zeta Pharma Egypt https://www.thepharmaletter.com/pharma-news/why-global-investors-are-turning-to-egyptian-pharma-a-plant-level-perspective-from-zeta-pharma-egypt https://www.thepharmaletter.com/pharma-news/why-global-investors-are-turning-to-egyptian-pharma-a-plant-level-perspective-from-zeta-pharma-egypt"
X Link 2026-02-12T09:44Z 25.4K followers, [---] engagements

"@DaiichiSankyoUS files for new Datroway indication in Japan https://www.thepharmaletter.com/biotech-news/daiichi-files-for-new-datroway-indication-in-japan https://www.thepharmaletter.com/biotech-news/daiichi-files-for-new-datroway-indication-in-japan"
X Link 2026-02-13T14:58Z 25.4K followers, [--] engagements

"@Amgen wins EC approval for Uplizna in gMG https://www.thepharmaletter.com/biotech-news/amgen-wins-ec-approval-for-uplizna-in-gmg https://www.thepharmaletter.com/biotech-news/amgen-wins-ec-approval-for-uplizna-in-gmg"
X Link 2026-02-13T14:58Z 25.4K followers, [--] engagements

"'I can buy data about [--] million people but none of those people have the right to that data' - James Heywood Patients Like Me #pharmasummit"
X Link 2015-02-26T12:13Z 25.4K followers, [--] engagements

"Catalonias biomedical raised [---] million euros in investment in [----] #biotech https://www.thepharmaletter.com/article/catalonia-s-biomedical-raised-102-million-euros-in-investment-in-2017 https://www.thepharmaletter.com/article/catalonia-s-biomedical-raised-102-million-euros-in-investment-in-2017"
X Link 2018-06-13T16:55Z 25.4K followers, [--] engagements

"@SironaBiochem rises as it pencils deal with Chinese #pharma https://www.thepharmaletter.com/article/sirona-biochem-rises-as-it-pencils-deal-with-chinese-pharma https://www.thepharmaletter.com/article/sirona-biochem-rises-as-it-pencils-deal-with-chinese-pharma"
X Link 2020-03-05T10:46Z 25.4K followers, [--] engagements

"@SFABiotech names CMO to strengthen management team https://www.thepharmaletter.com/article/sfa-therapeutics-names-cmo-to-strengthen-management-team https://www.thepharmaletter.com/article/sfa-therapeutics-names-cmo-to-strengthen-management-team"
X Link 2024-05-07T08:41Z 25.4K followers, [--] engagements

"SK bioscience advancing Zaire ebolavirus vaccine in CEPI and Merck & Co collab https://www.thepharmaletter.com/pharma-news/sk-bioscience-advancing-zaire-ebolavirus-vaccine-in-cepi-and-merck-co-collab https://www.thepharmaletter.com/pharma-news/sk-bioscience-advancing-zaire-ebolavirus-vaccine-in-cepi-and-merck-co-collab"
X Link 2026-01-23T09:24Z 25.4K followers, [---] engagements

"@GileadSciences publishes Trodelvy-Keytruda data in NEJM https://www.thepharmaletter.com/biotech-news/gilead-sciences-publishes-trodelvykeytruda-data-in-nejm https://www.thepharmaletter.com/biotech-news/gilead-sciences-publishes-trodelvykeytruda-data-in-nejm"
X Link 2026-01-23T09:25Z 25.4K followers, [--] engagements

"@GileadSciences' Trodelvy added to NCCN guidelines https://www.thepharmaletter.com/biotech-news/gilead-s-trodelvy-added-to-nccn-guidelines https://www.thepharmaletter.com/biotech-news/gilead-s-trodelvy-added-to-nccn-guidelines"
X Link 2026-01-29T08:47Z 25.4K followers, [--] engagements

"Hanmi expands efpeglenatide reach with Mexico distribution deal https://www.thepharmaletter.com/biotech-news/hanmi-expands-efpeglenatide-reach-with-mexico-distribution-deal https://www.thepharmaletter.com/biotech-news/hanmi-expands-efpeglenatide-reach-with-mexico-distribution-deal"
X Link 2026-01-29T08:50Z 25.4K followers, [---] engagements

"@WuXiBiologics Sinorda team up on bispecific antibody for IBD https://www.thepharmaletter.com/biotech-news/wuxi-biologics-sinorda-team-up-on-bispecific-antibody-for-ibd https://www.thepharmaletter.com/biotech-news/wuxi-biologics-sinorda-team-up-on-bispecific-antibody-for-ibd"
X Link 2026-01-29T16:23Z 25.4K followers, [--] engagements

"SK bioscience in-licenses RSV preventive antibody from Gates MRI https://www.thepharmaletter.com/biotech-news/sk-bioscience-inlicenses-rsv-preventive-antibody-from-gates-mri https://www.thepharmaletter.com/biotech-news/sk-bioscience-inlicenses-rsv-preventive-antibody-from-gates-mri"
X Link 2026-02-03T13:59Z 25.4K followers, [---] engagements

"@WuXiBiologics licenses trispecific immune engager to @VertexPharma https://www.thepharmaletter.com/biotech-news/wuxi-biologics-licenses-trispecific-immune-engager-to-vertex https://www.thepharmaletter.com/biotech-news/wuxi-biologics-licenses-trispecific-immune-engager-to-vertex"
X Link 2026-02-03T14:01Z 25.4K followers, [--] engagements

"Revenue falls for @pfizer while non-COVID growth offsets decline https://www.thepharmaletter.com/pharma-news/revenue-falls-for-pfizer-while-noncovid-growth-offsets-decline https://www.thepharmaletter.com/pharma-news/revenue-falls-for-pfizer-while-noncovid-growth-offsets-decline"
X Link 2026-02-04T11:09Z 25.4K followers, [---] engagements

"@Merck beats estimates but cautious on [----] https://www.thepharmaletter.com/pharma-news/merck-co-beats-estimates-but-cautious-on-2026 https://www.thepharmaletter.com/pharma-news/merck-co-beats-estimates-but-cautious-on-2026"
X Link 2026-02-04T11:10Z 25.4K followers, [--] engagements

"@Amgen posts double-digit revenue and EPS growth for [----] https://www.thepharmaletter.com/biotech-news/amgen-posts-double-digit-revenue-and-eps-growth-for-2025 https://www.thepharmaletter.com/biotech-news/amgen-posts-double-digit-revenue-and-eps-growth-for-2025"
X Link 2026-02-04T15:56Z 25.4K followers, [--] engagements

"@abbvie shares slide on perceived Humira reliance #AbbVie #Humira #Biopharma #PharmaNews #EarningsReaction #Biosimilars #Immunology #HealthcareInvesting #StockMarket #PatentCliff #DrugPipeline #MarketSentiment https://www.thepharmaletter.com/pharma-news/abbvie-shares-slide-on-perceived-humira-reliance https://www.thepharmaletter.com/pharma-news/abbvie-shares-slide-on-perceived-humira-reliance"
X Link 2026-02-05T18:29Z 25.4K followers, [--] engagements

"FTC and Express Scripts agree deal promised to lower drug costs #FTC #ExpressScripts #DrugCosts #PBMs #HealthcarePolicy #PrescriptionDrugs #DrugPricing #Competition #USHealthcare #PharmaNews #HealthEconomics #Regulation https://www.thepharmaletter.com/pharma-news/ftc-and-express-scripts-agree-deal-promised-to-lower-drug-costs https://www.thepharmaletter.com/pharma-news/ftc-and-express-scripts-agree-deal-promised-to-lower-drug-costs"
X Link 2026-02-05T18:32Z 25.4K followers, [---] engagements

"Bristol Myers posts modest Q4 growth outlines cautious outlook #BristolMyers #BMY #Q4Results #FY2025 #Earnings #PharmaNews #Biopharma #HealthcareInvesting #StockMarket #GrowthOutlook https://www.thepharmaletter.com/pharma-news/bristol-myers-posts-modest-q4-growth-outlines-cautious-outlook https://www.thepharmaletter.com/pharma-news/bristol-myers-posts-modest-q4-growth-outlines-cautious-outlook"
X Link 2026-02-05T18:34Z 25.4K followers, [---] engagements

"HHS drops 340B rebate pilot after court setback https://www.thepharmaletter.com/pharma-news/hhs-drops-340b-rebate-pilot-after-court-setback https://www.thepharmaletter.com/pharma-news/hhs-drops-340b-rebate-pilot-after-court-setback"
X Link 2026-02-09T15:22Z 25.4K followers, [---] engagements

"@sanofi's rilzabrutinib wins Breakthrough status from FDA for wAIHA https://www.thepharmaletter.com/sanofi-s-rilzabrutinib-wins-breakthrough-status-from-fda-for-waiha https://www.thepharmaletter.com/sanofi-s-rilzabrutinib-wins-breakthrough-status-from-fda-for-waiha"
X Link 2026-02-09T20:49Z 25.4K followers, [--] engagements

"Pandorum Technologies raises $18 million in Series B financing https://www.thepharmaletter.com/biotech-news/pandorum-technologies-raises-18-million-in-series-b-financing https://www.thepharmaletter.com/biotech-news/pandorum-technologies-raises-18-million-in-series-b-financing"
X Link 2026-02-10T15:47Z 25.4K followers, [--] engagements

"US FDA rejection sends @REGENXBIO shares sharply lower https://www.thepharmaletter.com/biotech-news/us-fda-rejection-sends-regenxbio-shares-sharply-lower https://www.thepharmaletter.com/biotech-news/us-fda-rejection-sends-regenxbio-shares-sharply-lower"
X Link 2026-02-10T15:49Z 25.4K followers, [---] engagements

"@AstraZeneca delivers continued growth toward $80 billion target https://www.thepharmaletter.com/pharma-news/astrazeneca-delivers-continued-growth-toward-80-billion-target https://www.thepharmaletter.com/pharma-news/astrazeneca-delivers-continued-growth-toward-80-billion-target"
X Link 2026-02-10T15:50Z 25.4K followers, [--] engagements

"Sanofi Ventures co-leads $85 million QuantX series B https://www.thepharmaletter.com/pharma-news/sanofi-ventures-co-leads-85-million-quantx-series-b https://www.thepharmaletter.com/pharma-news/sanofi-ventures-co-leads-85-million-quantx-series-b"
X Link 2026-02-10T15:51Z 25.4K followers, [--] engagements

"@AstraZenecas Imfinzi wins NICE nod as first perioperative IO treatment for MIBC https://www.thepharmaletter.com/biotech-news/astrazeneca-s-imfinzi-wins-nice-nod-as-first-perioperative-io-treatment-for-mibc https://www.thepharmaletter.com/biotech-news/astrazeneca-s-imfinzi-wins-nice-nod-as-first-perioperative-io-treatment-for-mibc"
X Link 2026-02-10T18:03Z 25.4K followers, [--] engagements

"Novo Nordisk commences legal action against Hims & Hers https://www.thepharmaletter.com/pharma-news/novo-nordisk-commences-legal-action-against-hims-and-hers https://www.thepharmaletter.com/pharma-news/novo-nordisk-commences-legal-action-against-hims-and-hers"
X Link 2026-02-10T18:04Z 25.4K followers, [---] engagements

"@GileadSciences 4th-qtr beats expectations but guidance disappoints https://www.thepharmaletter.com/pharma-news/gilead-sciences-4th-qtr-beats-expectations-but-guidance-disappoints https://www.thepharmaletter.com/pharma-news/gilead-sciences-4th-qtr-beats-expectations-but-guidance-disappoints"
X Link 2026-02-11T13:43Z 25.4K followers, [--] engagements

"@FujifilmHCUK opens $500 million UK biologics facility https://www.thepharmaletter.com/biotech-news/fujifilm-opens-500-million-uk-biologics-expansion-in-teesside https://www.thepharmaletter.com/biotech-news/fujifilm-opens-500-million-uk-biologics-expansion-in-teesside"
X Link 2026-02-11T13:44Z 25.4K followers, [--] engagements

"@UpstreamBio battered despite positive new verekitug data https://www.thepharmaletter.com/biotech-news/upstream-bio-battered-despite-positive-new-verekitug-data https://www.thepharmaletter.com/biotech-news/upstream-bio-battered-despite-positive-new-verekitug-data"
X Link 2026-02-12T09:43Z 25.4K followers, [--] engagements

"Mercks Beln Garijo to become CEO of @sanofi https://www.thepharmaletter.com/pharma-news/merck-s-belen-garijo-to-become-ceo-of-sanofi https://www.thepharmaletter.com/pharma-news/merck-s-belen-garijo-to-become-ceo-of-sanofi"
X Link 2026-02-13T14:55Z 25.4K followers, [---] engagements

"@VerricaPharma appoints Chris Chapman as CCO https://www.thepharmaletter.com/pharma-news/verrica-pharma-appoints-chris-chapman-as-cco https://www.thepharmaletter.com/pharma-news/verrica-pharma-appoints-chris-chapman-as-cco"
X Link 2026-02-13T14:59Z 25.4K followers, [--] engagements

"@Novartis Vanrafia Phase III data support slowing of kidney function decline in IgA nephropathy patients https://www.thepharmaletter.com/pharma-news/novartis-vanrafia-phase-iii-data-support-slowing-of-kidney-function-decline-in-iga-nephropathy-patients https://www.thepharmaletter.com/pharma-news/novartis-vanrafia-phase-iii-data-support-slowing-of-kidney-function-decline-in-iga-nephropathy-patients"
X Link 2026-02-13T15:00Z 25.4K followers, [---] engagements

"Crowdfunding could transform cancer treatment worldwide #pharma http://bit.ly/2mGKuZE http://bit.ly/2mGKuZE"
X Link 2017-02-28T15:02Z 25.4K followers, [--] engagements

"@LonzaGroup's @Synaffix and Sidewinder collaborate on ADCs https://www.thepharmaletter.com/biotechnology/lonza-s-synaffix-and-sidewinder-collaborate-on-adcs https://www.thepharmaletter.com/biotechnology/lonza-s-synaffix-and-sidewinder-collaborate-on-adcs"
X Link 2026-01-07T14:12Z 25.4K followers, [--] engagements

"ProBioGen and Zag Bio forge strategic CMC partnership https://www.thepharmaletter.com/biotechnology/probiogen-and-zag-bio-forge-strategic-cmc-partnership https://www.thepharmaletter.com/biotechnology/probiogen-and-zag-bio-forge-strategic-cmc-partnership"
X Link 2026-01-07T14:13Z 25.4K followers, [--] engagements

"@Genmab selects @AnthropicAI for AI-powered programs https://www.thepharmaletter.com/biotech-news/genmab-selects-anthropic-for-ai-powered-programs https://www.thepharmaletter.com/biotech-news/genmab-selects-anthropic-for-ai-powered-programs"
X Link 2026-01-08T13:05Z 25.4K followers, [--] engagements

"@EliLillyandCo confirms bid to acquire Ventyx Biosciences https://www.thepharmaletter.com/biotech-news/lilly-confirms-bid-to-acquire-ventyx-biosciences https://www.thepharmaletter.com/biotech-news/lilly-confirms-bid-to-acquire-ventyx-biosciences"
X Link 2026-01-08T13:12Z 25.4K followers, [--] engagements

"Teva inks deal with Royalty Pharma on potential vitiligo drug https://www.thepharmaletter.com/pharma-news/teva-inks-deal-with-royalty-pharma-on-potential-vitiligo-drug https://www.thepharmaletter.com/pharma-news/teva-inks-deal-with-royalty-pharma-on-potential-vitiligo-drug"
X Link 2026-01-12T14:13Z 25.4K followers, [---] engagements

"Sino Biopharmaceutical buys Hygieia https://www.thepharmaletter.com/biotech-news/sino-biopharmaceutical-buys-hygieia https://www.thepharmaletter.com/biotech-news/sino-biopharmaceutical-buys-hygieia"
X Link 2026-01-14T08:34Z 25.4K followers, [---] engagements

"@PharmaEssentia's sBLA in essential thrombocythemia accepted by FDA https://www.thepharmaletter.com/biotech-news/pharmaessentia-s-sbla-in-essential-thrombocythemia-accepted-by-fda https://www.thepharmaletter.com/biotech-news/pharmaessentia-s-sbla-in-essential-thrombocythemia-accepted-by-fda"
X Link 2026-01-14T08:40Z 25.4K followers, [--] engagements

"FDA grants Ipsens IPN60340 Breakthrough status https://www.thepharmaletter.com/pharma-news/fda-grants-ipsen-s-ipn60340-breakthrough-status https://www.thepharmaletter.com/pharma-news/fda-grants-ipsen-s-ipn60340-breakthrough-status"
X Link 2026-01-14T12:53Z 25.4K followers, [---] engagements

"First glimpse of new @novonordisk's CEOs strategy at JP Morgan https://www.thepharmaletter.com/pharma-news/first-glimpse-of-new-novo-nordisk-ceo-s-strategy-at-jp-morgan https://www.thepharmaletter.com/pharma-news/first-glimpse-of-new-novo-nordisk-ceo-s-strategy-at-jp-morgan"
X Link 2026-01-14T12:53Z 25.4K followers, [---] engagements

"Sandoz confirms EC approval of Ondibta biosimilar https://www.thepharmaletter.com/biosimilars-news/sandoz-confirms-ec-approval-of-ondibta-biosimilar https://www.thepharmaletter.com/biosimilars-news/sandoz-confirms-ec-approval-of-ondibta-biosimilar"
X Link 2026-01-15T09:30Z 25.4K followers, [---] engagements

"@hikmapharma launches denosumab biosimilars in USA https://www.thepharmaletter.com/biosimilars-news/hikma-launches-denosumab-biosimilars-in-usa https://www.thepharmaletter.com/biosimilars-news/hikma-launches-denosumab-biosimilars-in-usa"
X Link 2026-01-20T12:14Z 25.4K followers, [--] engagements

"Alteogen grants @GSKs Tesaro global rights to ALT-B4 https://www.thepharmaletter.com/biotech-news/alteogen-grants-gsks-tesaro-global-rights-to-altb4 https://www.thepharmaletter.com/biotech-news/alteogen-grants-gsks-tesaro-global-rights-to-altb4"
X Link 2026-01-20T12:16Z 25.4K followers, [---] engagements

"Exciva raises $59 million in Series B funding https://www.thepharmaletter.com/biotech-news/exciva-raises-59-million-in-series-b-funding https://www.thepharmaletter.com/biotech-news/exciva-raises-59-million-in-series-b-funding"
X Link 2026-01-20T15:02Z 25.3K followers, [--] engagements

"@pfizer sells @ViiVHC stake to @ShionogiUS https://www.thepharmaletter.com/pharma-news/pfizer-sells-viiv-stake-to-shionogi https://www.thepharmaletter.com/pharma-news/pfizer-sells-viiv-stake-to-shionogi"
X Link 2026-01-20T15:03Z 25.4K followers, [--] engagements

"@aspectbiosys and @novonordisk update on diabetes partnership https://www.thepharmaletter.com/pharma-news/aspect-biosystems-and-novo-nordisk-update-on-diabetes-partnership https://www.thepharmaletter.com/pharma-news/aspect-biosystems-and-novo-nordisk-update-on-diabetes-partnership"
X Link 2026-01-21T08:58Z 25.4K followers, [--] engagements

"Tribunal upholds Ipsens termination of R&D agreement with Galderma https://www.thepharmaletter.com/pharma-news/tribunal-upholds-ipsen-s-termination-of-r-and-d-agreement-with-galderma https://www.thepharmaletter.com/pharma-news/tribunal-upholds-ipsen-s-termination-of-r-and-d-agreement-with-galderma"
X Link 2026-01-23T09:22Z 25.4K followers, [---] engagements

"Ocular Therapeutix (@OCUTX) names David Robinson as global CCO https://www.thepharmaletter.com/pharma-news/ocular-therapeutix-names-david-robinson-as-global-cco https://www.thepharmaletter.com/pharma-news/ocular-therapeutix-names-david-robinson-as-global-cco"
X Link 2026-01-23T09:23Z 25.4K followers, [---] engagements

"Sagebrush sues Amgen over 340B program row https://www.thepharmaletter.com/biotech-news/sagebrush-sues-amgen-over-340b-program-row https://www.thepharmaletter.com/biotech-news/sagebrush-sues-amgen-over-340b-program-row"
X Link 2026-01-23T09:26Z 25.4K followers, [---] engagements

"Merck walks away from Revolution talks as price gap bites https://www.thepharmaletter.com/pharma-news/merck--co-walks-away-from-revolution-talks-as-price-gap-bites https://www.thepharmaletter.com/pharma-news/merck--co-walks-away-from-revolution-talks-as-price-gap-bites"
X Link 2026-01-27T09:26Z 25.4K followers, [---] engagements

"Advicenne gains marketing approval and reimbursement for Sibnayal in UAE https://www.thepharmaletter.com/biotech-news/advicenne-gains-marketing-approval-and-reimbursement-for-sibnayal-in-uae https://www.thepharmaletter.com/biotech-news/advicenne-gains-marketing-approval-and-reimbursement-for-sibnayal-in-uae"
X Link 2026-01-27T14:43Z 25.3K followers, [---] engagements

"@intelliatx shares leap as FDA lifts trial hold https://www.thepharmaletter.com/biotech-news/intellia-shares-leap-as-fda-lifts-trial-hold https://www.thepharmaletter.com/biotech-news/intellia-shares-leap-as-fda-lifts-trial-hold"
X Link 2026-01-28T09:41Z 25.3K followers, [--] engagements

"@antheiabio closes Series C to strengthen US drug production https://www.thepharmaletter.com/pharma-news/antheia-closes-series-c-to-strengthen-us-drug-production https://www.thepharmaletter.com/pharma-news/antheia-closes-series-c-to-strengthen-us-drug-production"
X Link 2026-01-28T09:43Z 25.3K followers, [--] engagements

"FDA accepts Otsukas centanafadine NDA for priority review https://www.thepharmaletter.com/pharma-news/fda-accepts-otsuka-s-centanafadine-nda-for-priority-review https://www.thepharmaletter.com/pharma-news/fda-accepts-otsuka-s-centanafadine-nda-for-priority-review"
X Link 2026-01-28T09:43Z 25.3K followers, [---] engagements

"@LonzaGroup delivers strong profitable growth in [----] https://www.thepharmaletter.com/generics-news/lonza-delivers-strong-profitable-growth-in-2025 https://www.thepharmaletter.com/generics-news/lonza-delivers-strong-profitable-growth-in-2025"
X Link 2026-01-29T08:39Z 25.4K followers, [--] engagements

"Global expansion of @Idorsias Quviviq continues https://www.thepharmaletter.com/pharma-news/global-expansion-of-idorsia-s-quviviq-continues https://www.thepharmaletter.com/pharma-news/global-expansion-of-idorsia-s-quviviq-continues"
X Link 2026-01-29T08:39Z 25.3K followers, [---] engagements

"@REGENXBIO shares hit by setback with gene therapies https://www.thepharmaletter.com/biotech-news/regenxbio-shares-hit-by-setback-with-gene-therapies https://www.thepharmaletter.com/biotech-news/regenxbio-shares-hit-by-setback-with-gene-therapies"
X Link 2026-01-29T08:50Z 25.4K followers, [--] engagements

"Takeda lifts guidance as growth brands offset Vyvanse drag https://www.thepharmaletter.com/pharma-news/takeda-lifts-guidance-as-growth-brands-offset-vyvanse-drag https://www.thepharmaletter.com/pharma-news/takeda-lifts-guidance-as-growth-brands-offset-vyvanse-drag"
X Link 2026-01-29T16:21Z 25.4K followers, [--] engagements

"@AstraZeneca commits $15 billion to China expansion strategy https://www.thepharmaletter.com/pharma-news/astrazeneca-commits-15bn-to-china-expansion-through-2030 https://www.thepharmaletter.com/pharma-news/astrazeneca-commits-15bn-to-china-expansion-through-2030"
X Link 2026-01-29T16:23Z 25.3K followers, [--] engagements

"Dupixent delivers for @sanofi again https://www.thepharmaletter.com/pharma-news/dupixent-delivers-for-sanofi-again https://www.thepharmaletter.com/pharma-news/dupixent-delivers-for-sanofi-again"
X Link 2026-01-29T16:24Z 25.4K followers, [--] engagements

"Trade group ponders how to attract trials to Belgium https://www.thepharmaletter.com/pharma-news/trade-group-ponders-how-to-attract-trials-to-belgium https://www.thepharmaletter.com/pharma-news/trade-group-ponders-how-to-attract-trials-to-belgium"
X Link 2026-02-03T08:53Z 25.4K followers, [--] engagements

"@KaziaTx advances nuclear PD-L1 degrader with pre-clinical data https://www.thepharmaletter.com/biotech-news/kazia-advances-nuclear-pdl1-degrader-with-pre-clinical-data https://www.thepharmaletter.com/biotech-news/kazia-advances-nuclear-pdl1-degrader-with-pre-clinical-data"
X Link 2026-02-03T08:55Z 25.4K followers, [--] engagements

"FDA issues CRL on @AstraZenecas Saphnelo BLA https://www.thepharmaletter.com/biotech-news/fda-issues-crl-on-astrazeneca-s-saphnelo-bla https://www.thepharmaletter.com/biotech-news/fda-issues-crl-on-astrazeneca-s-saphnelo-bla"
X Link 2026-02-03T14:01Z 25.4K followers, [---] engagements

"TIGIT blockers tipped for growth despite rocky record https://www.thepharmaletter.com/pharma-news/tigit-blockers-tipped-for-growth-despite-rocky-record https://www.thepharmaletter.com/pharma-news/tigit-blockers-tipped-for-growth-despite-rocky-record"
X Link 2026-02-04T15:55Z 25.4K followers, [--] engagements

"States widen generics antitrust case to Novartis in new filing https://www.thepharmaletter.com/generics-news/states-widen-generics-antitrust-case-to-novartis-in-new-filing https://www.thepharmaletter.com/generics-news/states-widen-generics-antitrust-case-to-novartis-in-new-filing"
X Link 2026-02-04T15:56Z 25.4K followers, [---] engagements

"@Novartis delivered high single-digit sales growth in [----] https://www.thepharmaletter.com/pharma-news/novartis-delivered-high-single-digit-sales-growth-in-2025 https://www.thepharmaletter.com/pharma-news/novartis-delivered-high-single-digit-sales-growth-in-2025"
X Link 2026-02-04T18:53Z 25.4K followers, [--] engagements

"@novonordisk tanks on financial guidance https://www.thepharmaletter.com/pharma-news/novo-nordisk-tanks-on-financial-guidance https://www.thepharmaletter.com/pharma-news/novo-nordisk-tanks-on-financial-guidance"
X Link 2026-02-04T18:55Z 25.4K followers, [--] engagements

"Forecast-topping @EliLillyandCo leaves Novo Nordisk in the shade https://www.thepharmaletter.com/pharma-news/forecast-topping-lilly-leaves-novo-nordisk-in-the-shade https://www.thepharmaletter.com/pharma-news/forecast-topping-lilly-leaves-novo-nordisk-in-the-shade"
X Link 2026-02-04T18:55Z 25.4K followers, [---] engagements

"Third Arc Bio closes $52 million Series A extension https://www.thepharmaletter.com/biotech-news/third-arc-bio-closes-52-million-series-a-extension https://www.thepharmaletter.com/biotech-news/third-arc-bio-closes-52-million-series-a-extension"
X Link 2026-02-04T18:56Z 25.4K followers, [---] engagements

"@veradermics announces pricing of upsized IPO #VeraDermics #IPO #BiotechIPO #IPOPricing #Nasdaq #Biotech #PharmaNews #HealthcareInvesting #CapitalMarkets #PublicOffering #StockMarket #Investing #Dermatology #Biopharma #WallStreet https://www.thepharmaletter.com/biotech-news/veradermics-announces-pricing-of-upsized-ipo https://www.thepharmaletter.com/biotech-news/veradermics-announces-pricing-of-upsized-ipo"
X Link 2026-02-05T18:27Z 25.4K followers, [--] engagements

"Sobi reports 4th-qrt and full year [----] results #Sobi #SOBI #FY2025 #Q4Results #Earnings #Biopharma #RareDiseases #FinancialResults #Stockholm #PharmaNews #HealthcareInvesting #InvestorRelations #NasdaqStockholm #HealthcareFinance #PharmaIndustry https://www.thepharmaletter.com/biotech-news/sobi-reports-4th-qrt-and-full-year-2025-results https://www.thepharmaletter.com/biotech-news/sobi-reports-4th-qrt-and-full-year-2025-results"
X Link 2026-02-05T18:28Z 25.4K followers, [--] engagements

"@novonordisk appoints new head of its US business #NovoNordisk #Leadership #USBusiness #PharmaNews #Healthcare #Biopharma #Executive #USMarket #PharmaIndustry #Innovation #GlobalHealthcare https://www.thepharmaletter.com/pharma-news/novo-nordisk-appoints-new-head-of-its-us-business https://www.thepharmaletter.com/pharma-news/novo-nordisk-appoints-new-head-of-its-us-business"
X Link 2026-02-05T18:30Z 25.4K followers, [--] engagements

"Braveheart Bio names Marc Evanchik CSO https://www.thepharmaletter.com/biotech-news/braveheart-bio-names-marc-evanchik-cso https://www.thepharmaletter.com/biotech-news/braveheart-bio-names-marc-evanchik-cso"
X Link 2026-02-06T16:13Z 25.4K followers, [--] engagements

"SVF Vaccines to take over Novakand in reverse acquisition https://www.thepharmaletter.com/pharma-news/svf-vaccines-to-take-over-novakand-in-reverse-acquisition https://www.thepharmaletter.com/pharma-news/svf-vaccines-to-take-over-novakand-in-reverse-acquisition"
X Link 2026-02-06T16:13Z 25.4K followers, [--] engagements

"Novo Nordisk to sue Hims & Hers over illegal compounding https://www.thepharmaletter.com/generics-news/novo-nordisk-to-sue-hims-and-hers-over-illegal-compounding https://www.thepharmaletter.com/generics-news/novo-nordisk-to-sue-hims-and-hers-over-illegal-compounding"
X Link 2026-02-06T16:14Z 25.4K followers, [---] engagements

"EMA validates Santheras MAA for #Raxone for Lebers hereditary optic neuropathy http://t.co/7sp0rH0Wyj #pharma http://bit.ly/1rOu8Pi http://bit.ly/1rOu8Pi"
X Link 2014-06-06T06:30Z 25.4K followers, [--] engagements

"We were at the @novonordisk briefing at #EASD2014 this week hearing about Ryzodeg Tresiba and Xultophy http://t.co/6TVF3Hgjze #diabetes http://bit.ly/XufDlR http://bit.ly/XufDlR"
X Link 2014-09-19T13:06Z 25.4K followers, [--] engagements

"Percentage of sales coming from emerging markets has gone from 14% in [----] to 24% in [----] #FTPharma"
X Link 2014-11-17T15:42Z 25.4K followers, [--] engagements

"Spain to reduce the prices of new #biosimilars by up to 30% http://t.co/cROCA7caK4 http://bit.ly/1BzJlpi http://bit.ly/1BzJlpi"
X Link 2015-03-12T17:45Z 25.4K followers, [--] engagements

"Sanofis dengue vaccine gets regulatory approval in Brazil @sanofi http://bit.ly/1NTPqkE http://bit.ly/1NTPqkE"
X Link 2015-12-29T12:49Z 25.4K followers, [--] engagements

"Endo pulls out of deals with Acerus and VIVAS #pharma http://bit.ly/1n43q4J@ENDP http://bit.ly/1n43q4J@ENDP"
X Link 2016-01-06T15:02Z 25.4K followers, [--] engagements

"Indian Govts Start-up #India campaign to boost innovation in biotech/ pharma sectors #pharmaceuticals #biotech http://bit.ly/1Wr0tY1 http://bit.ly/1Wr0tY1"
X Link 2016-01-19T15:16Z 25.4K followers, [--] engagements

"Genmab gets @US_FDA approval of #Arzerra to treat #CLL #biotech http://bit.ly/1WtSglH http://bit.ly/1WtSglH"
X Link 2016-01-20T13:07Z 25.4K followers, [--] engagements

". @AstraZeneca presents positive data on ceftazidime-avibactam for multi-drug gram-negative infections #pharma http://bit.ly/1Nm9pbB http://bit.ly/1Nm9pbB"
X Link 2016-04-12T09:13Z 25.4K followers, [--] engagements

"Read our Exclusive: Takeda Tsunami hits Japan #pharma http://bit.ly/23uSosz http://bit.ly/23uSosz"
X Link 2016-04-13T16:29Z 25.4K followers, [--] engagements

"Paula Salmikangas CAT chair EMA says p'ships with big #pharma are bringing breakthrough cell therapies closer #scrm16"
X Link 2016-05-18T09:12Z 25.4K followers, [--] engagements

"UK patients first in Europe to benefit from new skin cancer treatment #biotech http://bit.ly/2617bfH http://bit.ly/2617bfH"
X Link 2016-06-17T07:56Z 25.4K followers, [--] engagements

"Celgene partners with UK's Oxford Sciences Innovation @Celgene #pharma http://bit.ly/TPL-Celgene-OSI http://bit.ly/TPL-Celgene-OSI"
X Link 2017-01-12T17:42Z 25.4K followers, [--] engagements

"Celgene partners with UK's Oxford Sciences Innovation #pharma @Celgene http://bit.ly/TPL-Celgene-OSI http://bit.ly/TPL-Celgene-OSI"
X Link 2017-01-12T22:02Z 25.4K followers, [--] engagements

"First company gains GMP approval in medicinal cannabis production #pharma http://bit.ly/2keAtlS http://bit.ly/2keAtlS"
X Link 2017-01-24T20:47Z 25.4K followers, [--] engagements

"Generic anticancer drug to rival AstraZeneca's Iressa in China @AstraZeneca http://bit.ly/TPL-Iressa-China http://bit.ly/TPL-Iressa-China"
X Link 2017-02-20T15:33Z 25.4K followers, [--] engagements

"Why #pharma needs help dealing with the wicked problem of vaccine shortages @IFPMA @sanofipasteur http://bit.ly/2q2TV8O http://bit.ly/2q2TV8O"
X Link 2017-05-09T16:36Z 25.4K followers, [--] engagements

"Lynparza data shows survival and quality of life benefit #pharma #ASCO17 @AstraZeneca http://bit.ly/2rsBtqE http://bit.ly/2rsBtqE"
X Link 2017-06-02T16:12Z 25.4K followers, [--] engagements

". @OxfordBioMedica #biotech inks $100 million supply agreement https://www.thepharmaletter.com/article/oxford-biomedica-inks-100-million-supply-agreement https://www.thepharmaletter.com/article/oxford-biomedica-inks-100-million-supply-agreement"
X Link 2017-07-06T14:57Z 25.4K followers, [--] engagements

"Artificial intelligence firm hires ex-GSK exec to lead drug discovery @benevolent_ai @benevolent_bio @GSK #biotech https://www.thepharmaletter.com/article/artificial-intelligence-firm-hires-ex-gsk-exec-to-lead-drug-discovery https://www.thepharmaletter.com/article/artificial-intelligence-firm-hires-ex-gsk-exec-to-lead-drug-discovery"
X Link 2017-08-22T11:34Z 25.4K followers, [--] engagements

"Indian Patent Office at last approves Pfizers patent for Prevnar [--] @pfizer @MSF_Ind @PanaceaBiotec #pharma https://www.thepharmaletter.com/article/indian-patent-office-at-last-approves-pfizer-s-patent-for-prevnar-13 https://www.thepharmaletter.com/article/indian-patent-office-at-last-approves-pfizer-s-patent-for-prevnar-13"
X Link 2017-08-23T09:17Z 25.4K followers, [--] engagements

"Lundbeck picks up Parkinsons candidate with [---] million-euro buy of Prexton #pharma @MerckHealthcare @Lundbeck @LundbeckUS https://www.thepharmaletter.com/article/lundbeck-picks-up-parkinson-s-candidate-with-905-million-euro-buy-of-prexton https://www.thepharmaletter.com/article/lundbeck-picks-up-parkinson-s-candidate-with-905-million-euro-buy-of-prexton"
X Link 2018-03-16T14:40Z 25.4K followers, [--] engagements

"Cloud-based COTS solutions are pharmas future in research @HalloranConsult #pharma https://www.thepharmaletter.com/article/cloud-based-cots-solutions-are-pharma-s-future-in-research https://www.thepharmaletter.com/article/cloud-based-cots-solutions-are-pharma-s-future-in-research"
X Link 2018-03-27T11:50Z 25.4K followers, [--] engagements

"Omeicos Opthalmics names first CEO #biotech @omeicos https://www.thepharmaletter.com/article/omeicos-opthalmics-names-its-first-ceo https://www.thepharmaletter.com/article/omeicos-opthalmics-names-its-first-ceo"
X Link 2018-04-27T15:48Z 25.4K followers, [--] engagements

"Merck KGaA's Healthcare CEO looking 'beyond treatment' to combat diabetes #pharma @MerckHealthcare @merckgroup https://www.thepharmaletter.com/article/merck-kgaa-s-healthcare-ceo-looking-beyond-treatment-to-combat-diabetes https://www.thepharmaletter.com/article/merck-kgaa-s-healthcare-ceo-looking-beyond-treatment-to-combat-diabetes"
X Link 2018-05-17T13:33Z 25.4K followers, [--] engagements

"Robert Hopkins and Arun Upadhyay take senior roles at @Ocugen https://www.thepharmaletter.com/article/ocugen-appoints-new-cmo-and-cso https://www.thepharmaletter.com/article/ocugen-appoints-new-cmo-and-cso"
X Link 2022-09-02T08:47Z 25.4K followers, [--] engagements

"@TeijinAramid inks exclusive license deal with @Novartis https://www.thepharmaletter.com/article/teijin-pharma-inks-exclusive-license-deal-with-novartis https://www.thepharmaletter.com/article/teijin-pharma-inks-exclusive-license-deal-with-novartis"
X Link 2023-03-07T10:20Z 25.4K followers, [--] engagements

"@BharatBiotech collaborates with Bilthoven Biologicals (@BBio_nl) to strengthen global polio eradication https://www.thepharmaletter.com/article/bharat-biotech-collaborates-with-bilthoven-biologicals-to-strengthen-global-polio-eradication https://www.thepharmaletter.com/article/bharat-biotech-collaborates-with-bilthoven-biologicals-to-strengthen-global-polio-eradication"
X Link 2024-05-09T08:16Z 25.4K followers, [----] engagements

"Amryt trio join @PoolbegPharma leadership team https://www.thepharmaletter.com/article/amryt-trio-join-poolbeg-leadership https://www.thepharmaletter.com/article/amryt-trio-join-poolbeg-leadership"
X Link 2023-11-13T11:22Z 25.4K followers, [----] engagements

"@PhrmMar and Luye Pharmas NDA for lurbinectedin accepted in China https://www.thepharmaletter.com/article/pharmamar-and-luye-pharma-s-nda-for-lurbinectedin-accepted-in-china https://www.thepharmaletter.com/article/pharmamar-and-luye-pharma-s-nda-for-lurbinectedin-accepted-in-china"
X Link 2023-06-14T08:55Z 25.4K followers, [---] engagements

"Europe lines up another [--] million doses of coronavirus vaccine @valnevaSE https://www.thepharmaletter.com/article/europe-lines-up-another-60-million-doses-of-coronavirus-vaccine https://www.thepharmaletter.com/article/europe-lines-up-another-60-million-doses-of-coronavirus-vaccine"
X Link 2021-01-14T10:08Z 25.4K followers, [--] engagements

".@4dpharmaplc merging with Longevity https://www.thepharmaletter.com/article/4d-pharma-merging-with-longevity https://www.thepharmaletter.com/article/4d-pharma-merging-with-longevity"
X Link 2020-10-23T09:49Z 25.4K followers, [--] engagements

"To treat cancer don't just combine but prime says Nanobiotix CEO #ASCO2019 #ASCO19 #biotech #oncology #research https://www.thepharmaletter.com/article/to-treat-cancer-don-t-just-combine-but-prime-says-nanobiotix-ceo https://www.thepharmaletter.com/article/to-treat-cancer-don-t-just-combine-but-prime-says-nanobiotix-ceo"
X Link 2019-05-24T14:33Z 25.4K followers, [--] engagements

"@cansinobio_inc's inhaled #COVID19 vaccine Convidecia Air approved in China https://www.thepharmaletter.com/article/cansinobio-s-inhaled-covid-19-vaccine-convidecia-air-approved-in-china https://www.thepharmaletter.com/article/cansinobio-s-inhaled-covid-19-vaccine-convidecia-air-approved-in-china"
X Link 2022-09-06T15:04Z 25.4K followers, [--] engagements

"Expert committee to assess pricing of @sanofi India's diabetes med Soliqua https://www.thepharmaletter.com/article/expert-committee-to-assess-pricing-of-sanofi-india-s-diabetes-med-soliqua https://www.thepharmaletter.com/article/expert-committee-to-assess-pricing-of-sanofi-india-s-diabetes-med-soliqua"
X Link 2023-10-12T08:43Z 25.4K followers, [---] engagements

"Crowdfunding could transform cancer treatment worldwide #pharma http://bit.ly/2mGKuZE http://bit.ly/2mGKuZE"
X Link 2017-02-28T15:02Z 25.4K followers, [--] engagements

".@JanssenEMEA targeting innovation way beyond me-too drugs in neuroscience says Lars Leppin https://www.thepharmaletter.com/article/janssen-targeting-innovation-way-beyond-me-too-drugs-in-neuroscience-says-lars-leppin https://www.thepharmaletter.com/article/janssen-targeting-innovation-way-beyond-me-too-drugs-in-neuroscience-says-lars-leppin"
X Link 2021-12-02T14:40Z 25.4K followers, [--] engagements

"Novo Nordisk CSO warns NASH market will develop slowly urges all to 'moderate expectations' @novonordisk https://www.thepharmaletter.com/article/novo-nordisk-cso-warns-nash-market-will-develop-slowly-urges-all-to-moderate-expectations https://www.thepharmaletter.com/article/novo-nordisk-cso-warns-nash-market-will-develop-slowly-urges-all-to-moderate-expectations"
X Link 2017-11-28T15:41Z 25.4K followers, [--] engagements

"@moderna_tx files for approval of RSV vaccine MRNA-1345 https://www.thepharmaletter.com/article/moderna-files-for-approval-of-rsv-vaccine-mrna-1345 https://www.thepharmaletter.com/article/moderna-files-for-approval-of-rsv-vaccine-mrna-1345"
X Link 2023-07-07T09:10Z 25.4K followers, [--] engagements

"@SamsungBioepis' Hadlima biosimilar approved in Canada https://www.thepharmaletter.com/article/samsung-bioepis-hadlima-biosimilar-approved-in-canada https://www.thepharmaletter.com/article/samsung-bioepis-hadlima-biosimilar-approved-in-canada"
X Link 2023-01-05T12:55Z 25.4K followers, [---] engagements

"Aplidin to be re-evaluated by the EMA https://www.thepharmaletter.com/aplidin-to-be-re-evaluated-by-the-ema https://www.thepharmaletter.com/aplidin-to-be-re-evaluated-by-the-ema"
X Link 2024-07-15T14:21Z 25.4K followers, [---] engagements

"Expert view by @Bayer head of oncology Robert LaCaze: Maximizing patient impact in oncology: R&D strategies #pharma http://bit.ly/2dMWX9F http://bit.ly/2dMWX9F"
X Link 2016-10-06T11:13Z 25.4K followers, [--] engagements

"@PhrmMar releases top-line data on Zepzelca and Tecentriq combo in lung cancer https://www.thepharmaletter.com/pharmamar-releases-top-line-data-on-zepzelca-and-tecentriq-combo-in-lung-cancer https://www.thepharmaletter.com/pharmamar-releases-top-line-data-on-zepzelca-and-tecentriq-combo-in-lung-cancer"
X Link 2024-10-17T20:29Z 25.4K followers, [---] engagements

". @GileadSciences to file for US approval of filgotinib this year @GalapagosNV #biotech https://www.thepharmaletter.com/article/gilead-to-file-for-us-approval-of-filgotinib-this-year https://www.thepharmaletter.com/article/gilead-to-file-for-us-approval-of-filgotinib-this-year"
X Link 2019-07-03T11:46Z 25.4K followers, [--] engagements

"Following positive Phase II data @synlogic_tx advances SYNB1934 to Phase III https://www.thepharmaletter.com/article/following-positive-phase-ii-data-synlogic-advances-synb1934-to-phase-iii https://www.thepharmaletter.com/article/following-positive-phase-ii-data-synlogic-advances-synb1934-to-phase-iii"
X Link 2022-10-20T12:05Z 25.4K followers, [--] engagements

"@OxCanTech inks development deal with ex-Google AI experts Hypatia AI https://www.thepharmaletter.com/oct-inks-development-deal-with-ex-google-ai-experts-hypatia-ai https://www.thepharmaletter.com/oct-inks-development-deal-with-ex-google-ai-experts-hypatia-ai"
X Link 2024-11-05T18:50Z 25.4K followers, [---] engagements

"In Episode [--] of The Pharma Letter Podcast we speak with Nidia Afonso EMEA compound market access lead at @JanssenGlobal about her company's efforts to keep patient empowerment at the heart of the patient journey"
X Link 2021-11-01T12:00Z 25.4K followers, [--] engagements

"In the runup to #AAIC22 Simon Wentworth spoke with AAIC director of global science initiatives Chris Weber @alzassociation https://www.thepharmaletter.com/article/looking-forward-to-aaic-2022-with-global-science-director-chris-weber https://www.thepharmaletter.com/article/looking-forward-to-aaic-2022-with-global-science-director-chris-weber"
X Link 2022-07-22T13:58Z 25.4K followers, [--] engagements

"''In [----] private companies invested [--] billion in AMR research that's [--] times more than public sector.'' - Nina Grundmann senior manager global health and economic policy @IFPMA @EconomistEvents #EconAMR #pharma"
X Link 2019-03-26T12:30Z 25.4K followers, [--] engagements

"Endo pulls out of deals with Acerus and VIVAS #pharma http://bit.ly/1n43q4J@ENDP http://bit.ly/1n43q4J@ENDP"
X Link 2016-01-06T15:02Z 25.4K followers, [--] engagements

"NeuroVive gets $4 million for genetic mitochondrial diseases program #biotech https://www.thepharmaletter.com/article/neurovive-gets-4-million-for-genetic-mitochondrial-diseases-program https://www.thepharmaletter.com/article/neurovive-gets-4-million-for-genetic-mitochondrial-diseases-program"
X Link 2018-08-29T15:26Z 25.4K followers, [--] engagements

"Beyfortus cuts RSV hospitalizations by 82% in babies RWE shows https://www.thepharmaletter.com/article/beyfortus-cuts-rsv-hospitalizations-by-82-in-babies-rwe-shows https://www.thepharmaletter.com/article/beyfortus-cuts-rsv-hospitalizations-by-82-in-babies-rwe-shows"
X Link 2024-05-02T14:35Z 25.4K followers, [---] engagements

". @PureTechH acquires LYT-100 to treat #Lymphedema #biotech #deals #immunology #research #UK https://www.thepharmaletter.com/article/puretech-acquires-lyt-100-to-treat-lymphedema https://www.thepharmaletter.com/article/puretech-acquires-lyt-100-to-treat-lymphedema"
X Link 2019-07-17T16:40Z 25.4K followers, [--] engagements

"The Pharma Letter #Podcast Episode [--] The rise of AI in drug discovery AION Labs BioMed X Institute #AI https://www.thepharmaletter.com/article/the-pharma-letter-podcast-episode-9-the-rise-of-ai-in-drug-discovery https://www.thepharmaletter.com/article/the-pharma-letter-podcast-episode-9-the-rise-of-ai-in-drug-discovery"
X Link 2021-12-31T10:04Z 25.4K followers, [--] engagements

"Why digital procurement is a game changer for the pharmaceutical industry https://www.thepharmaletter.com/article/why-digital-procurement-is-a-game-changer-for-the-healthcare-and-pharmaceutical-industry https://www.thepharmaletter.com/article/why-digital-procurement-is-a-game-changer-for-the-healthcare-and-pharmaceutical-industry"
X Link 2021-06-23T09:40Z 25.4K followers, [--] engagements

"Given its strong tech and computer science base could Japan be a sleeping giant in AI-based drug discovery @elix_ai @shinya_elix https://www.thepharmaletter.com/article/elix-chief-exec-aims-to-lead-japan-s-ai-drug-discovery-field https://www.thepharmaletter.com/article/elix-chief-exec-aims-to-lead-japan-s-ai-drug-discovery-field"
X Link 2022-05-13T09:29Z 25.4K followers, [--] engagements

"Data on Adaptimmune's trial with afami-cel published in The Lancet https://www.thepharmaletter.com/article/data-on-adaptimmune-s-trial-with-afami-cel-published-in-the-lancet https://www.thepharmaletter.com/article/data-on-adaptimmune-s-trial-with-afami-cel-published-in-the-lancet"
X Link 2024-04-02T17:48Z 25.4K followers, [---] engagements

"EC approves AbbVies Skyrizi for Crohns disease @abbvie @Boehringer #biotech https://www.thepharmaletter.com/article/ec-approves-abbvie-s-skyrizi-for-crohn-s-disease https://www.thepharmaletter.com/article/ec-approves-abbvie-s-skyrizi-for-crohn-s-disease"
X Link 2022-11-24T15:38Z 25.4K followers, [--] engagements

"EC approves @Roche's eye drug Vabysmo https://www.thepharmaletter.com/article/ec-approves-roche-s-eye-drug-vabysmo https://www.thepharmaletter.com/article/ec-approves-roche-s-eye-drug-vabysmo"
X Link 2022-09-20T09:01Z 25.4K followers, [--] engagements

"@In8bio reports promising results for leukemia cell therapy https://www.thepharmaletter.com/biotechnology/in8bio-reports-promising-results-for-leukemia-cell-therapy https://www.thepharmaletter.com/biotechnology/in8bio-reports-promising-results-for-leukemia-cell-therapy"
X Link 2025-02-13T09:03Z 25.4K followers, [---] engagements

"@moderna_tx submits EMA filing for updated COVID-19 jab https://www.thepharmaletter.com/article/moderna-submits-ema-filing-for-updated-covid-19-jab https://www.thepharmaletter.com/article/moderna-submits-ema-filing-for-updated-covid-19-jab"
X Link 2023-07-04T11:12Z 25.4K followers, [--] engagements

"@MedsPatentPool and @MedinCell sign license deal to fight malaria https://www.thepharmaletter.com/article/medicines-patent-pool-and-medincell-sign-license-deal-to-fight-malaria https://www.thepharmaletter.com/article/medicines-patent-pool-and-medincell-sign-license-deal-to-fight-malaria"
X Link 2022-09-15T13:43Z 25.4K followers, [--] engagements

". @genentech ready to spend over $700 million on cancer vaccines deal with Vaccibody #biotech https://www.thepharmaletter.com/article/genentech-ready-to-spend-over-700-million-on-cancer-vaccines-deal-with-vaccibody https://www.thepharmaletter.com/article/genentech-ready-to-spend-over-700-million-on-cancer-vaccines-deal-with-vaccibody"
X Link 2020-10-02T10:31Z 25.4K followers, [--] engagements

"Vaccitech rebrands as @BarinthusBio https://www.thepharmaletter.com/article/vaccitech-rebrands-as-barinthus-biotherapeutics https://www.thepharmaletter.com/article/vaccitech-rebrands-as-barinthus-biotherapeutics"
X Link 2023-11-08T10:49Z 25.4K followers, [---] engagements

"Sanofis dengue vaccine gets regulatory approval in Brazil @sanofi http://bit.ly/1NTPqkE http://bit.ly/1NTPqkE"
X Link 2015-12-29T12:49Z 25.4K followers, [--] engagements

"Paula Salmikangas CAT chair EMA says p'ships with big #pharma are bringing breakthrough cell therapies closer #scrm16"
X Link 2016-05-18T09:12Z 25.4K followers, [--] engagements

".@US_FDA approves Nivestym the second biosimilar to Neupogen cleared in the USA #biosimilar @Amgen @pfizer_news https://www.thepharmaletter.com/article/fda-approves-nivestym-the-second-biosimilar-to-neupogen-cleared-in-the-usa https://www.thepharmaletter.com/article/fda-approves-nivestym-the-second-biosimilar-to-neupogen-cleared-in-the-usa"
X Link 2018-07-23T09:40Z 25.4K followers, [--] engagements

"Lynparza data shows survival and quality of life benefit #pharma #ASCO17 @AstraZeneca http://bit.ly/2rsBtqE http://bit.ly/2rsBtqE"
X Link 2017-06-02T16:12Z 25.4K followers, [--] engagements

"One to watch: India's increasing bid to develop its own innovation and manufacturing capacity (independent from China) @IdmaPresident https://www.thepharmaletter.com/article/local-manufacture-of-35-apis-underway-as-india-seeks-self-reliance https://www.thepharmaletter.com/article/local-manufacture-of-35-apis-underway-as-india-seeks-self-reliance"
X Link 2022-04-26T08:49Z 25.4K followers, [--] engagements

"GSK rare diseases expert heads to cell therapy catapult #biotech @GSK @CGTCatapult https://www.thepharmaletter.com/article/gsk-rare-diseases-expert-heads-to-cell-therapy-catapult https://www.thepharmaletter.com/article/gsk-rare-diseases-expert-heads-to-cell-therapy-catapult"
X Link 2018-06-06T16:21Z 25.4K followers, [--] engagements

"Despite argenx Vyvdura approval quest for definitive myasthenia gravis cure persists in Japan https://www.thepharmaletter.com/article/despite-argenx-vyvdura-approval-quest-for-definitive-myasthenia-gravis-cure-persists-in-japan https://www.thepharmaletter.com/article/despite-argenx-vyvdura-approval-quest-for-definitive-myasthenia-gravis-cure-persists-in-japan"
X Link 2024-01-31T10:18Z 25.4K followers, [---] engagements

"Expanded US FDA approval of @Sarepta's Elevidys in DMD https://www.thepharmaletter.com/article/expanded-us-fda-approval-of-elevidys-in-dmd https://www.thepharmaletter.com/article/expanded-us-fda-approval-of-elevidys-in-dmd"
X Link 2024-06-24T08:29Z 25.4K followers, [---] engagements

"@BioMed_X Institute enters new collaboration with @Merck https://www.thepharmaletter.com/article/biomed-x-institute-enters-new-collaboration-with-merck https://www.thepharmaletter.com/article/biomed-x-institute-enters-new-collaboration-with-merck"
X Link 2022-08-01T14:52Z 25.4K followers, [--] engagements

"UK patients first in Europe to benefit from new skin cancer treatment #biotech http://bit.ly/2617bfH http://bit.ly/2617bfH"
X Link 2016-06-17T07:56Z 25.4K followers, [--] engagements

"R&D tax credits continue to boost pharmaceutical sector but firms must keep on top of regulatory changes #pharma http://bit.ly/1SfM6GB http://bit.ly/1SfM6GB"
X Link 2016-01-12T13:06Z 25.4K followers, [--] engagements

"Keith Thompson of @CTCatapult predicted in interview that cell & gene therapies would surpass the global biologics market #scrm16 #biotech"
X Link 2016-05-18T12:54Z 25.4K followers, [--] engagements

"#COVID19 vaccine #ZD1222 expands into US Phase III trial @AstraZeneca https://www.thepharmaletter.com/article/covid-19-vaccine-zd1222-expands-into-us-phase-iii-trial https://www.thepharmaletter.com/article/covid-19-vaccine-zd1222-expands-into-us-phase-iii-trial"
X Link 2020-09-01T15:22Z 25.4K followers, [--] engagements

"Why companies should be optimistic about innovation in the NHS #Government #pharma @GKStrategy @EJCJones93 https://www.thepharmaletter.com/article/why-companies-should-be-optimistic-about-innovation-in-the-nhs https://www.thepharmaletter.com/article/why-companies-should-be-optimistic-about-innovation-in-the-nhs"
X Link 2019-05-10T15:36Z 25.4K followers, [--] engagements

"Microbiome trial boosts MaaT sets path for EU marketing bid https://www.thepharmaletter.com/biotechnology/microbiome-trial-boosts-maat-sets-path-for-eu-marketing-bid https://www.thepharmaletter.com/biotechnology/microbiome-trial-boosts-maat-sets-path-for-eu-marketing-bid"
X Link 2025-01-10T09:41Z 25.4K followers, [---] engagements

"@LinkGevity wins investment from the KQ Labs Program https://www.thepharmaletter.com/linkgevity-wins-investment-from-the-kq-labs-program https://www.thepharmaletter.com/linkgevity-wins-investment-from-the-kq-labs-program"
X Link 2025-01-22T13:07Z 25.4K followers, [--] engagements

"First company gains GMP approval in medicinal cannabis production #pharma http://bit.ly/2keAtlS http://bit.ly/2keAtlS"
X Link 2017-01-24T20:47Z 25.4K followers, [--] engagements

"US FDA approves Novartis combo heart failure drug Entresto ahead of schedule http://t.co/r5QYghsvWJ http://bit.ly/1LS5pSk http://bit.ly/1LS5pSk"
X Link 2015-07-08T14:35Z 25.4K followers, [--] engagements

"Phase III Winrevair trial meets endpoint says @Merck https://www.thepharmaletter.com/phase-3-winrevair-trial-meets-endpoint-says-merck https://www.thepharmaletter.com/phase-3-winrevair-trial-meets-endpoint-says-merck"
X Link 2024-11-26T09:40Z 25.4K followers, [----] engagements

"Spain to reduce the prices of new #biosimilars by up to 30% http://t.co/cROCA7caK4 http://bit.ly/1BzJlpi http://bit.ly/1BzJlpi"
X Link 2015-03-12T17:45Z 25.4K followers, [--] engagements

"Novartis heart failure drug needs monitoring for safety says AdverseEvents http://t.co/SC0BcmFUti #research #novartis #pharma http://bit.ly/1HD4f85 http://bit.ly/1HD4f85"
X Link 2015-07-17T11:32Z 25.4K followers, [--] engagements

"Uncertain future for S1P receptor modulators in Crohns disease says @Healthcare_GD https://www.thepharmaletter.com/uncertain-future-for-s1p-receptor-modulators-in-crohns-disease-says-globaldata https://www.thepharmaletter.com/uncertain-future-for-s1p-receptor-modulators-in-crohns-disease-says-globaldata"
X Link 2024-10-14T08:25Z 25.4K followers, [---] engagements

".@MylanNews #biosimilar as good as #Herceptin in advanced #breast #cancer study reveals #ASCO16 http://bit.ly/289AxHy http://bit.ly/289AxHy"
X Link 2016-06-04T06:16Z 25.4K followers, [--] engagements

"'Time is the killer of value in this sector' - George Freeman #ftpharma"
X Link 2014-11-18T09:29Z 25.4K followers, [--] engagements

". @GileadSciences to invest a massive $5 billion-plus in Belgian biotech firm #arthritis #rheumatics #Belgium #biotech #mergers #acquisitions #deals @GalapagosNV @GileadSciences #inglammatorydiseases #research #respiratory #pulmonary #USA https://www.thepharmaletter.com/article/gilead-to-invest-a-massive-5-billion-plus-in-belgian-biotech-firm https://www.thepharmaletter.com/article/gilead-to-invest-a-massive-5-billion-plus-in-belgian-biotech-firm"
X Link 2019-07-16T08:09Z 25.4K followers, [--] engagements

"Best practices to determine fitness-for-purpose of RWE in oncology @IQVIA_global #RWE https://www.thepharmaletter.com/article/best-practices-to-determine-fitness-for-purpose-of-rwe-in-oncology-studies https://www.thepharmaletter.com/article/best-practices-to-determine-fitness-for-purpose-of-rwe-in-oncology-studies"
X Link 2021-12-13T10:27Z 25.4K followers, [--] engagements

". @Oncodesign_SA and @Servier reach milestone in Parkinsons collaboration #biotech https://www.thepharmaletter.com/article/oncodesign-and-servier-reach-milestone-in-parkinson-s-collaboration https://www.thepharmaletter.com/article/oncodesign-and-servier-reach-milestone-in-parkinson-s-collaboration"
X Link 2020-02-18T12:29Z 25.4K followers, [--] engagements

"Expert view by @Bayer head of oncology Robert LaCaze - Maximizing patient impact in oncology: R&D strategies #pharma http://bit.ly/2dMWX9F http://bit.ly/2dMWX9F"
X Link 2016-10-06T15:33Z 25.4K followers, [--] engagements

"Menarinis elacestrant accepted for priority review by the @US_FDA https://www.thepharmaletter.com/article/menarini-s-elacestrant-accepted-for-priority-review-by-the-us-fda https://www.thepharmaletter.com/article/menarini-s-elacestrant-accepted-for-priority-review-by-the-us-fda"
X Link 2022-08-12T15:50Z 25.4K followers, [--] engagements

"Eisai buys rights to Rohypnol in Japan from Chugai and Roche #pharma http://bit.ly/TPL-Eisai-Rohypnol http://bit.ly/TPL-Eisai-Rohypnol"
X Link 2017-01-16T16:08Z 25.4K followers, [--] engagements

"@coeptistx shops local for its university CAR-T tech https://www.thepharmaletter.com/article/coeptis-shops-local-for-its-university-car-t-tech https://www.thepharmaletter.com/article/coeptis-shops-local-for-its-university-car-t-tech"
X Link 2022-09-22T14:03Z 25.4K followers, [--] engagements

"Read our Exclusive: Takeda Tsunami hits Japan #pharma http://bit.ly/23uSosz http://bit.ly/23uSosz"
X Link 2016-04-13T16:29Z 25.4K followers, [--] engagements

"#pharma cos now demanding return on digital investments but some still risk being left behind says @_DiMeSociety CEO Jennifer Goldsack https://www.thepharmaletter.com/article/pharma-cos-now-demanding-return-on-digital-investments-but-some-still-risk-being-left-behind-says-dime-society-s-jennifer-goldsack https://www.thepharmaletter.com/article/pharma-cos-now-demanding-return-on-digital-investments-but-some-still-risk-being-left-behind-says-dime-society-s-jennifer-goldsack"
X Link 2022-10-25T08:27Z 25.4K followers, [--] engagements

"Cell and gene manufacturers benefit from surge in FDA drug approvals https://www.thepharmaletter.com/article/cell-and-gene-manufacturers-benefit-from-surge-in-fda-drug-approvals https://www.thepharmaletter.com/article/cell-and-gene-manufacturers-benefit-from-surge-in-fda-drug-approvals"
X Link 2024-05-09T14:36Z 25.4K followers, [---] engagements

"Our #pharma ethics interview with @millerbioethics from @BioethicsIntl on @GoodPharmaScore http://bit.ly/29pdorX http://bit.ly/29pdorX"
X Link 2016-06-30T12:32Z 25.4K followers, [--] engagements

"Setback for Merck & Co in battle to treat endometrial cancer https://www.thepharmaletter.com/article/setback-for-merck-in-battle-to-treat-endometrial-cancer https://www.thepharmaletter.com/article/setback-for-merck-in-battle-to-treat-endometrial-cancer"
X Link 2024-05-13T17:02Z 25.4K followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing